Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...